| |
| Trade Name | RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM |
| Classification Name | coronary drug-eluting stent |
| Applicant | MEDTRONIC VASCULAR |
| PMA Number | P110013 |
| Supplement Number | S005 |
| Date Received | 07/17/2012 |
| Decision Date | 02/22/2013 |
| Product Code | |
| Docket Number | 13M-0343 |
| Notice Date | 03/22/2013 |
| Advisory Committee |
Cardiovascular |
| Clinical Trials |
NCT00726453
|
| Supplement Type | panel track |
| Supplement Reason | labeling change - indications |
| Expedited Review Granted? | No |
| Combination Product |
Yes
|
| Information About: |
Labeling, Approval Order, Summary of Safety and Effectiveness |
Approval Order Statement Approval for the resolute integrity zotarolimus-eluting coronary stent system. This device is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length <= 35 mm in native coronary arteries with reference vessel diameters of 2. 25 mm to 4. 2 mm. |
| Approval Order |
Approval Order
|
| Post-Approval Study | Show Report Schedule and Study Progress |